Naveris Inc. is a molecular diagnostics company developing and commercializing novel blood and saliva tests to enhance the early detection and clinical management of viral-associated cancers. The company’s NavDx® blood test, which uses proprietary technology to detect tumor tissue modified viral (TTMV®)-HPV DNA, is in use at leading cancer treatment centers and academic medical centers throughout the United States.